|Selected research from leading health care experts whose findings have a direct bearing on public policies effecting medical progress. Research is chosen based on its quality and relevance by the Medical Progress Today editorial staff.||
A study in the Annals of Internal Medicine recently posted online found that “rofecoxib (Vioxx) increases the risk for acute myocardial infarction, and risk increases further with higher doses.”
The study used a “time-matched, nested, case-control approach and Quebec’s administrative health databases” to evaluate 113,927 elderly patients without previous heart disease who began NSAID treatment between January 1, 1999 and June 30, 2002. The researchers also noted that “there were not increased risks associated with use of celecoxib…or the other NSAIDs” followed in the study.
The authors concluded that “new agents with COX-2 inhibitory potency similar to or greater than that of [Vioxx] should be used only with extreme caution, even in populations at relatively low risk for cardiovascular events.”
|home spotlight commentary research events news about contact links archives|